Accelovance has signed a merger agreement with Linical, a CRO based in Asia in the fields of oncology, immunology, and neurology. The transaction is scheduled to close in early Q2 subject to certain closing conditions.
This union creates a market-leading contract research organization with significant global scale across North America, Europe, and Asia Pacific. Both organizations have a 13-year history as trusted partners to biopharmaceutical companies, providing comprehensive and flexible clinical development solutions.
The new company will offer clients oncology expertise, with combined scientific strength in early and late phases of clinical development. In addition, the company will provide leadership in many other therapeutic areas. Together, the companies’ services cover the entire drug life cycle, offering clients a one-stop provider for drug development, clinical research, a patient-focused call center, medical affairs, and post-marketing services.
“This is an exciting milestone for Accelovance, allowing us to further expand our global bandwidth. Linical’s expertise in oncology and immunology aligns perfectly with our therapeutic focus, and their strong heritage in neurology further enhances our service offering for clients,” Stephen J. Trevisan, CEO of Accelovance said. “We are pleased to be working together with an organization that shares our mission of delivering exceptional execution to our clients in clinical research.”
With a common emphasis on quick delivery with highly precise data and deep therapeutic expertise, Linical and Accelovance have a strong mutual track record of success serving the unique needs of emerging and established biopharmaceutical clients.